(Q61150129)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21494260%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

title

Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21494260%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21494260%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Olivier Kosmider

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21494260%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Bruno Quesnel

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21494260%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Claude Preudhomme

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21494260%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Michaela Fontenay

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21494260%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

13

P Fenaux

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21494260%20AND%20SRC:MED&resulttype=core&format=json

Groupe Francophone des Myelodysplasies (GFM)

28 January 2020

15

object named as

Groupe Francophone des Myelodysplasies (GFM)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21494260%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

6

O Beyne-Rauzy

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21494260%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Véronique Gelsi-Boyer

9

object named as

V Gelsi-Boyer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21494260%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

author name string

T Cluzeau

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21494260%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

V Mansat-De Mas

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21494260%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

F Dreyfus

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21494260%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

N Vey

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21494260%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

S Raynaud

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21494260%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

L Adès

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21494260%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

publication date

15 April 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21494260%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21494260%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

volume

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21494260%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21494260%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

page(s)

1147-1152

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21494260%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/leu.2011.71

28 January 2020

exact match

0 references

cites work

Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.71

7 January 2021

Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.71

7 January 2021

Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.71

7 January 2021

Mutation in TET2 in myeloid cancers

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.71

7 January 2021

TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs).

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.71

7 January 2021

Acquired mutations in TET2 are common in myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.71

7 January 2021

Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.71

7 January 2021

Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.71

7 January 2021

Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.71

7 January 2021

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.71

7 January 2021

Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.71

7 January 2021

Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.71

7 January 2021

Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.71

7 January 2021

Predictive value of pretreatment risk group and baseline LDH levels in MDS patients receiving azacitidine treatment

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.71

7 January 2021

Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.71

7 January 2021

Proposals for the classification of the myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.71

7 January 2021

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.71

7 January 2021

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.71

7 January 2021

Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.71

7 January 2021

Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.71

7 January 2021

Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.71

7 January 2021

Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.71

7 January 2021

CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.71

7 January 2021

Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.71

7 January 2021

DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.71

7 January 2021

Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.71

7 January 2021

Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.71

7 January 2021